Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 13OTHER 10NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 39Breast 10Gynecologic 3Endocrine 2Thoracic 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Rectal Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 40Carboplatin 40Paclitaxel 34Radiotherapy 32Docetaxel 19Pemetrexed 17Gemcitabine 17Etoposide 17Bevacizumab 11Radiosurgery 9Magnetic Resonance Spectroscopy 9Ramucirumab 8durvalumab 7Taxes 7Cetuximab 7pembrolizumab 6Specimen Handling 6Erlotinib Hydrochloride 6Irinotecan 5Gene Expression Profiling 5Filgrastim 5cediranib 4Vinorelbine 4Polymerase Chain Reaction 4Neoadjuvant Therapy 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Amplified Fragment Length Polymorphism Analysis 4tremelimumab 3osimertinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Capecitabine × Thoracic × Clear all
NCT00107250 2023-08-04

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Canadian Cancer Trials Group

Phase 1 Completed
50 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡